Skip to main content
Premium Trial:

Request an Annual Quote

20 Percent Boost in Agilent’s Life Science Sales Drives 7 Percent Q2 Profit Spike

NEW YORK (GenomeWeb News) - Agilent Technologies said late yesterday that fiscal second-quarter revenues increased 6 percent as R&D spending increased 1 percent and profit climbed 7 percent.     
 
Revenue for the company's Bio-Analytical Measurement segment increased 15 percent to $428 million from $372 million year over year and Life Sciences revenue was up 20 percent to $194 million, the company said.
 
The company attributed the growth to strong sales of liquid chromatography and LC/mass spectrometry instruments and its comparative genomic hybridization microarrays. 
 
Total receipts for the three months ended April 31 increased to $1.32 billion from $1.24 billion year over year.
 
R&D spending increased to $173 million from $172 million year over year.
 
The company said net income rose to $123 million from $115 million in the year-ago period.
 
Agilent said it had around $2.05 billion in cash and cash equivalents as of April 31.
 
For the third quarter of 2007, the company said it expects revenues between $1.36 billion and $1.4 billion.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.